Can a single antibody help people with HIV pause their pills?
NCT ID NCT04860323
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether an experimental antibody called VRC01 could help people with HIV control the virus after they stop taking their daily HIV medication. Thirteen people who had received VRC01 or a placebo in an earlier study and later got HIV took part. They paused their HIV drugs under close monitoring to see how long their immune system could keep the virus in check.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VRC01 (an experimental antibody)
What this could lead to
If successful, this could point toward ways to help some people with HIV control the virus without daily medication.
What could go wrong
This is a very small, early study with only 13 participants. It is designed to gather information, not to prove a treatment works. Stopping HIV medication carries risks, including virus rebound.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blantyre CRS
Blantyre, Malawi
-
CAPRISA eThekwini CRS
Durban, South Africa
-
Gaborone CRS
Gaborone, Botswana
-
Kliptown Soweto CRS
Johannesburg, South Africa
-
Malawi CRS
Lilongwe, Malawi
-
Milton Park CRS
Harare, Zimbabwe
-
Rustenburg CRS
Rustenburg, South Africa
-
Seke South CRS
Harare, Zimbabwe
-
Spilhaus CRS
Harare, Zimbabwe
-
Vulindlela CRS
Durban, South Africa
-
Ward 21 CRS
Johannesburg, South Africa